Physician profile
Cathleen Morris
NPI 1285707570
$4,112.22
in general payments reported to CMS, 2019-2025
28 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $335 · 2021: $979 · 2022: $862 · 2023: $733 · 2024: $636 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $985.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $842.98 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $520.28 | 2021-2025 | |
| Lilly USA, LLC | $381.74 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $227.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $181.20 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.64 | 2020-2022 | |
| Pfizer INC. | $114.30 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $111.86 | 2019-2024 | Farxiga, Fasenra |
| Eisai INC. | $80.70 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.85 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.35 | 2019-2021 | |
| Exact Sciences Corporation | $46.32 | 2023-2025 | Cologuard Collection Kit |
| Radius Health, INC. | $41.47 | 2019-2024 | Tymlos |
| Amarin Pharma, INC. | $39.96 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $38.43 | 2019-2021 | |
| Daiichi Sankyo INC. | $34.19 | 2021 | |
| Astellas Pharma US INC | $33.59 | 2021-2023 | Myrbetriq |
| Esperion Therapeutics, INC. | $31.34 | 2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $29.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.94 | 2020-2021 | |
| Allergan, INC. | $26.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $17.21 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Idorsia Pharmaceuticals US INC | $15.78 | 2022 | |
| Ethicon INC. | $15.58 | 2024 | Monarch Platform |
| Dexcom, INC. | $13.83 | 2021 | |
| Abbott Laboratories | $13.11 | 2024 | Freestyle Libre |
| Ibsa Pharma INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathleen Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.